Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases.

The company’s lead drug candidate, SLV213, is a novel small molecule antiviral therapy with activity against a broad range of viruses that threaten global health, including SARS-CoV-2, the coronavirus that causes COVID-19. In addition, SLV213 has activity against Ebola, Nipah, and Marburg viruses, as well as Chagas disease, a parasitic disease endemic to South and Central America but also found in the southern half of the United States.

By rapidly developing SLV213 for COVID-19, Selva Therapeutics aims to bring a valuable treatment to the market that has the potential to fight multiple life-threatening infectious diseases and protect global health.